PT-141
Bremelanotide / Vyleesi
PT-141 (bremelanotide) is a melanocortin-receptor agonist FDA-approved as Vyleesi only for acquired, generalized low sexual desire (HSDD) in premenopausal women: 1.75 mg SubQ at least 45 minutes before sex, no more than 1 dose per 24 hours or 8 per month. Use in men or postmenopausal women is off-label.
Half-life
~2.7 hours
Typical Dose
1.75 mg per use (label dose)
Route
subcutaneous
Category
sexual_health
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How PT-141 is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 1.75 mg per use (label dose). Half-life: ~2.7 hours. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
FDA-approved (Vyleesi, 2019) for premenopausal women with acquired, generalized HSDD; the label says it is not indicated for postmenopausal women, for men, or to enhance sexual performance. Two Phase 3 randomized trials (RECONNECT) found statistically significant gains in desire and less distress versus placebo; nausea, flushing and headache were more common. The label caps use at 1 dose per 24 hours and says more than 8 doses a month is not recommended, because each dose transiently raises blood pressure and frequent dosing raises the risk of skin darkening. Earlier intranasal studies in men with erectile dysfunction did not lead to approval for that use.
- FDA prescribing information (Vyleesi)
- Two Phase 3 randomized trials (2019)
Used by practitioners for sexual dysfunction in both sexes. Start at 0.5–1 mg to assess tolerance. Nausea management with ondansetron if needed.
- Sexual medicine practitioner protocols
- Urology and endocrinology clinic reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for PT-141 and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy
PT-141: common questions
What is PT-141?
PT-141 (bremelanotide) is a melanocortin-receptor agonist FDA-approved as Vyleesi only for acquired, generalized low sexual desire (HSDD) in premenopausal women: 1.75 mg SubQ at least 45 minutes before sex, no more than 1 dose per 24 hours or 8 per month. Use in men or postmenopausal women is off-label.
How is PT-141 dosed?
PT-141 is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 1.75 mg per use (label dose). Clinical (human trials): 1.75 mg SubQ (label dose, premenopausal women); As needed, at least 45 min before activity; max 1 dose per 24 h, 8 per month; Per-use (no cycling required). Expert (practitioner protocols): 0.5–1.75 mg, titrate up to the 1.75 mg label dose; As needed (max 1 dose per 24 h, 8 per month); Per-use. These ranges describe what has been studied or used; they are not a prescription.
Is PT-141 FDA-approved?
Yes. PT-141 is an FDA-approved prescription medicine; uses outside its approved indication are off-label.
What is the half-life of PT-141?
DoseCraft's library lists a half-life of ~2.7 hours. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use PT-141?
Listed contraindications: Uncontrolled hypertension; Cardiovascular disease; Pregnancy.
Free Guides for PT-141
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.